Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (squamous NSCLC, combination chemotherapy) - Addendum to commission A19-31]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (non-squamous NSCLC, combination chemotherapy) - Addendum to commission A19-30]
2019	NIHR Health Services and Delivery Research programme	Investigating the contribution of physician associates (PAs) to secondary care in England: a mixed methods study
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Galcanezumab (migraine) - Addendum to commission A19-28]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Paediatric deep brain stimulation
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas not treatable by surgery - 3rd addendum to commission H16-02C]
2019	Canary Health Service	[PACS system and its possible application in the management of NO-DICOM clinical objects]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - 2nd addendum to commission H16-02B]
2019	Health Quality Ontario (HQO)	Cervical Artificial Disc Replacement Versus Fusion for Cervical Degenerative Disc Disease: A Health Technology Assessment
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the liver and the intrahepatic bile ducts - 2nd addendum to commission H16-02D]
2019	Technology Assessment at SickKids (TASK)	A microcosting and cost-consequence analysis of genomic testing strategies (including trios) in autism spectrum disorder: an update
2019	Health Technology Wales (HTW)	Procalcitonin point-of-care testing for initial assessment of suspected sepsis
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	Platelet Rich Plasma (PRP) in Achilles Tendon Rupture (ATR) healing
2019	Technology Assessment at SickKids (TASK)	The economic evaluation of early intervention with anti-tumor necrosis factor-α treatments in pediatric Crohn's disease
2019	Health Technology Wales (HTW)	Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Minimally invasive pancreaticoduodenectomy: the evidence
2019	NIHR Health Technology Assessment programme	Models Of Reablement Evaluation: a mixed methods evaluation of a complex intervention (The MORE project)
2019	Technology Assessment at SickKids (TASK)	A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: a Canadian analysis
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Axicabtagene ciloleucel]
2019	Health Technology Wales (HTW)	Synovasure® Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Galcanezumab (migraine) - Second Addendum to Commission A19-28]
2019	Health Quality Ontario (HQO)	Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment
2019	Health Technology Wales (HTW)	Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for liver transplantations - rapid report]
2019	Health Technology Wales (HTW)	Continuous glucose monitoring systems for managing diabetes in pregnant women
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2019	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Scientific evidence and evidence gaps in social care regarding assessment routines and interventions for persons with substance abuse, and their families]
2019	Health Quality Ontario (HQO)	Perspectives of Pregnant People and Clinicians on Noninvasive Prenatal Testing: A Systematic Review and Qualitative Meta-synthesis
2019	Health Technology Wales (HTW)	Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mexiletine]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nintedanib (idiopathic pulmonary fibrosis) - Addendum to Commission A19-36]
2019	Health Quality Ontario (HQO)	Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment
2019	NIHR Health Services and Delivery Research programme	Innovation to enhance health in care homes: rapid evidence synthesis
2019	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Assessment and interventions in care and services for older adults - an evidence map]
2019	Ontario Health	Osseointegrated Prosthetic Implants for People With Lower-Limb Amputation: A Health Technology Assessment
2019	Health Technology Wales (HTW)	Occipital nerve stimulation for medically refractory chronic cluster headache
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegvaliase (phenylketonuria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Health Sciences Institute in Aragon (IACS)	Efficacy, effectiveness and safety of intraoperative radiotherapy in breast carcinoma
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pegvaliase]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	The Effectiveness and cost-effectiveness of Surgical Treatments for womEn with stRess urinary incontinence: an evidence synthesis (ESTER)
2019	Health Sciences Institute in Aragon (IACS)	Detection of diabetes' complications. Diabetic retinopathy. Economic evaluation of ultra-wide field scanning laser
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37]
2019	European Network for Health Technology Assessment (EUnetHTA)	Stool DNA testing for early detection of colorectal cancer
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report]
2019	Ontario Health	Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes: A Health Technology Assessment
2019	European Network for Health Technology Assessment (EUnetHTA)	C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019	European Network for Health Technology Assessment (EUnetHTA)	Robot-assisted surgery in thoracic and visceral indications
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Public Health Research (PHR) programme	NAP SACC UK: a feasibility cluster randomised controlled trial in child care settings to increase physical activity and healthy eating in 2-4 year olds
2019	European Network for Health Technology Assessment (EUnetHTA)	Irreversible electroporation for the treatment of liver and pancreatic cancer
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fremanezumab (migraine) - Addendum to Commission A19-44]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Chondroitin sulfate in osteoarthritis
2019	Ontario Health	Minimally Invasive Glaucoma Surgery: A Budget Impact Analysis and Evaluation of Patients’ Experiences, Preferences, and Values
2019	European Network for Health Technology Assessment (EUnetHTA)	Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease)
2019	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41]
2019	NIHR Health Technology Assessment programme	Behavioural Activation Therapy for Depression after Stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression
2019	European Network for Health Technology Assessment (EUnetHTA)	Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Turoctocog alfa pegol - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	A group memory rehabilitation programme for people with traumatic brain injuries: the ReMemBrIn RCT
2019	NIHR Public Health Research (PHR) programme	Adapting a falls prevention exercise programme with and for older people with visual impairment: a feasibility study
2019	European Network for Health Technology Assessment (EUnetHTA)	Regional hyperthermia for high-risk soft tissue sarcoma treatment
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2019	Belgian Health Care Knowledge Centre (KCE)	Polyvalent immunoglobulins – Part 1: A rapid review
2019	European Network for Health Technology Assessment (EUnetHTA)	Screening for osteoporosis in the general population
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cemiplimab - Benefit assessment according to §35a Social Code Book V]
2019	European Network for Health Technology Assessment (EUnetHTA)	Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (plaque psoriasis) - Addendum to Commission A19-41]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Human dermal allograft for massive rotator cuff tears
2019	NIHR Health Technology Assessment programme	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
2019	European Network for Health Technology Assessment (EUnetHTA)	Point-of-care tests (POCT): D-dimer and troponin
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Volanesorsen (familial chylomicronaemia syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pomalidomide (multiple myeloma) - Addendum to Commission A19-50]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 18 years and older, with R117H mutation) - Benefit assessment according to §35a Social Code Book V]
2019	NIHR Health Technology Assessment programme	Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 2 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 years and older, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Closed vs open systems for the preparation and administration of cytostatic and other hazardous drugs (NIOSH Group 1): analysis of the scientific evidence, costs and organisational requirements]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, from 12 to < 24 months, with gating mutations) - Benefit assessment according to §35a Social Code Book V]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Indications, utility and use of ultrasound in primary care]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor, cystic fibrosis, 12 years and older, with F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Use of incentive spirometry for the prevention of pulmonary complications following surgery]
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Controlled and uncontrolled donation after circulatory death with regional normothermic or hypothermic perfusion based on extracorporeal membrane oxygenation for kidney and liver transplants]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V]
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Clinical practice visits: a rapid review
2019	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Measurement of gastric residual volume during enteral feeding in patients hospitalized in the intensive care unit]
2019	Belgian Health Care Knowledge Centre (KCE)	Bariatric surgery : an HTA report on the efficacy, safety and cost-effectiveness
2019	Basque Office for Health Technology Assessment (OSTEBA)	[Methodological project: Synthesis of information in support of multicriteria decision analysis (MCDA) for decision making]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (new therapeutic indication, Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]